The next big approach in Alzheimer’s has been dealt a blow, and there are plenty more tau-targeting contenders.
Daridorexant can't reach the heights of its first pivotal study win, but a pooled analysis could still save it.
Adaptimmune and Allogene led numerous cell therapy companies higher over the Asco period, while Cytomx and Arvinas suffered the biggest losses.
Aduro finally runs up the white flag on Sting agonism, and becomes a listed shell for Chinook Therapeutics.
Roche secures a front-line liver cancer label, but rival data at Asco show that the competition isn’t resting on its laurels.